Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Las Vegas Sands enters its October 21 earnings report down 18% over the past month, with the Street trimming targets even as most bulls hold their ratings, a gap between conviction and price action that defines the stock's setup right now.
The analyst picture is the most active part of this story. Macquarie's Chad Beynon cut his price target to $56 from $62 on October 7, keeping his Outperform rating intact. That follows a wave of post-Q2 reductions in late July, when Goldman Sachs, JP Morgan, Morgan Stanley, Barclays, Mizuho and Stifel all trimmed targets while maintaining positive or neutral stances. The consensus remains hold, with seven analysts at that rating, but the direction of travel on targets has been unambiguously lower. The stock closed at $36.31 on October 6, against a Macquarie target of $56 and a Goldman target of $55, a gap that reflects either a deep discount opportunity or a Street that has been too slow to follow the stock down. Argus Research took the more decisive step in late July, downgrading to Hold from Buy with no target attached.
The bull case rests on valuation and capital returns. At roughly 6.6x EV/EBITDA and a P/E below 11, LVS trades well below its historical 12x to 14x EBITDA range. The company's Singapore asset is valued by some analysts at $40 to $50 per share on its own. Bulls point to around $8 billion of available liquidity, ongoing buybacks, and $12.5 billion of Macau and Marina Bay Sands development projects expected to clear a 20% return on invested capital. The EV/EBIT factor score ranks in the 73rd percentile, consistent with a stock that looks inexpensive on an operating-earnings basis. Bears counter that the 2022 sale of the Las Vegas Venetian left the company entirely dependent on Macau and Singapore, two markets with meaningful political and regulatory risk, and that VIP and premium mass spending remain vulnerable to any softening in Asia-Pacific consumer demand. EPS momentum scores rank in the 22nd and 34th percentiles over 90 and 30 days respectively, a sign that near-term earnings revisions have been running against the stock.
Positioning carries no particular stress signal heading into the print. Short interest is low at 2.6% of free float and has barely moved, up less than 0.3% on the week and 6.5% over the past month. Borrow costs have eased sharply, down 31% on the week to 0.40%, and availability is extremely loose at over 4,300%, meaning shares are plentiful for anyone who wants to short. Options traders are also relaxed: the put/call ratio of 0.45 is fractionally below its 20-day average of 0.46 and near the 52-week low of 0.42, a reading that leans mildly bullish rather than defensively positioned. There is no squeeze setup and no crowded short. The ORTEX short score of 40.7 has barely moved across the past two weeks, consistent with a stock where short-side pressure is not the story.
The ownership structure is worth noting because it shapes how the stock trades. Miriam Adelson holds a 13D activist stake covering 52.7% of shares as last disclosed in August, up from 51.5% previously. She and the Sheldon G. Adelson Family Trust together account for over 51% of shares outstanding in institutional disclosures, which means the effective free float is narrow and institutional positions outside the founding family are modest. BlackRock added roughly 578,000 shares through September, and State Street added over 919,000. T. Rowe Price added 844,000. These are incremental buys against a stock that has fallen hard, not a rush for the exit. Notably, retail attention has picked up: the ORTEX Wikipedia views signal has a z-score of nearly 2.0 against the stock's own 90-day history, though this is an attention measure rather than a revenue indicator.
The last earnings print, in late July, produced a modest 1.2% one-day gain that extended to nearly 7% over the following five trading sessions. The next report on October 21 arrives with the stock down sharply from that level and the Street's targets well above current prices. The key question into that print is whether management's commentary on Macau mass-market recovery pacing and the trajectory of Marina Bay Sands construction costs narrows or widens the gap between where analysts have targets and where the market is pricing the shares.
See the live data behind this article on ORTEX.
Open LVS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
